Skip to content

Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease

Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05830110
Enrollment
30
Registered
2023-04-26
Start date
2023-03-01
Completion date
2026-06-01
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

vibrotactile

Brief summary

The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for PD symptoms and thus restore motor function.

Detailed description

Up to thirty adults with bilateral, moderate stage idiopathic PD will be enrolled in this longitudinal study. Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals. This longitudinal protocol will be open-ended to enable continued treatment to those interested / motivated. Study treatment will consist of daily, four-hour vibrotactile Coordinated Reset (vCR) stimulation sessions on a continual basis. All daily vCR stimulation sessions will occur at the participant's home (ON-medication) and can be broken up into two, two-hour blocks (with no more than 12 hours between stimulation blocks) to be less cumbersome and better integrate into the participant's daily life. Daily home-based treatment will be unsupervised, though timely support is guaranteed by Synergic Medical Technologies (SMT) support staff when needed (e.g., when usability or IT issues arise). Daily stimulation / device usage will be automatically logged by the device and continuously monitored by SMT staff, meanwhile participants will keep a med diary so we can monitor their med usage (and how it relates to extended exposure) over time. Participants will be able to transition to an as-needed basis with treatment after four months and once they are familiar with the treatment and their body's response to it, to better alleviate PD symptoms.

Interventions

Gloves providing vibrotactile coordinated reset stimulation

Gloves providing sham vibrotactile coordinated reset stimulation

Sponsors

Synergic Medical Technologies, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals.

Eligibility

Sex/Gender
ALL
Age
45 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* between the ages 45 and 90 * diagnosis of bilateral, moderate stage idiopathic PD * qualify for EEG procedures

Exclusion criteria

* on dopamine agonist medications and exhibiting compulsive behaviors

Design outcomes

Primary

MeasureTime frameDescription
Movement Disorder Society - Change in Universal Parkinson Disease Rating Scale (MDS-UPDRS)baseline, 2 months, 4 monthsChange in MDS-UPDRS score using Part 3 of the scale.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPhan Luu, PhD

Synergic Medical Technologies, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026